Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phagenesis appoints chairman and CEO to take new dysphagia treatment to market

This article was originally published in Clinica

Executive Summary

Phagenesis, a UK company developing a neurostimulation technology to treat dysphagia caused by stroke, has appointed Henry Hyde-Thomson chairman and Daniel Green CEO. Mr Hyde-Thomson is a serial entrepreneur and is the founder and chairman of UK-based private equity firm AngloScientific. Mr Green was most recently co-founder and CEO of regenerative medicine firm RepRegen. Both will lead Phagenesis’ efforts in taking its first dysphagia treatment product to market. Dysphagia is the inability to swallow properly; at least 50% of stroke patients are affected by this condition. Phagenesis, which was spun out of the University of Manchester in 2007, has developed a device that delivers electrical pulses to the throat region. These pulses stimulate the nerve cells that run directly to the part of the brain which controls swallowing and helps to restore this function. Other causes include diseases like multiple sclerosis, Parkinson’s disease, Alzheimer’s and motor neurone disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel